Vaxxinity (Vaxxinity) Cash, Cash Equivalents, Marketable Securities : $30.40 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Cash, Cash Equivalents, Marketable Securities?

Vaxxinity's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($55.85 Mil) to Sep. 2023 ($42.52 Mil) but then stayed the same from Sep. 2023 ($42.52 Mil) to Dec. 2023 ($30.40 Mil).

Vaxxinity's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($144.89 Mil) to Dec. 2022 ($86.83 Mil) and declined from Dec. 2022 ($86.83 Mil) to Dec. 2023 ($30.40 Mil).

Vaxxinity Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Vaxxinity's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity Cash, Cash Equivalents, Marketable Securities Chart

Vaxxinity Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

0.48

31.14

144.89

86.83

30.40

Vaxxinity Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial											86.83	67.58	55.85	42.52	30.40

Vaxxinity Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Vaxxinity (OTCPK:VAXX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Vaxxinity Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Vaxxinity's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxxinity (Vaxxinity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Odyssey Way, Merritt Island, FL, USA, 32953

Website

https://www.vaxxinity.com

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.

Executives

Sumita Ray	officer: Chief Legal Officer, Secretary	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp	10 percent owner	P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano	director	209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese	director, officer: Executive Chairman	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu	director, 10 percent owner, officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc	10 percent owner	25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss	10 percent owner	126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile	officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig	director	625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui	director	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292